A1AIL

lesinurad

Created:2024-03-19
Last modified:  2024-09-18

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count38
Chiral Atom Count0
Bond Count41
Aromatic Bond Count16
2D diagram of A1AIL
Toggle HydrogenToggle Labels

Chemical Component Summary

Namelesinurad
Synonyms{[(4M)-5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
Systematic Name (OpenEye OEToolkits)2-[[5-bromanyl-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]ethanoic acid
FormulaC17 H14 Br N3 O2 S
Molecular Weight404.281
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01O=C(O)CSc1nnc(Br)n1c1ccc(C2CC2)c2ccccc12
SMILESCACTVS3.385OC(=O)CSc1nnc(Br)n1c2ccc(C3CC3)c4ccccc24
SMILESOpenEye OEToolkits2.0.7c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4
Canonical SMILESCACTVS3.385 OC(=O)CSc1nnc(Br)n1c2ccc(C3CC3)c4ccccc24
Canonical SMILESOpenEye OEToolkits2.0.7 c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4
InChIInChI1.06 InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
InChIKeyInChI1.06 FGQFOYHRJSUHMR-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB11560 
NameLesinurad
Groups
  • approved
  • investigational
DescriptionLesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.
Synonyms
  • Lesinurad
  • {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
Brand Names
  • Duzallo
  • Zurampic
IndicationFor use, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
Categories
  • Acetates
  • Acids, Acyclic
  • Antigout Preparations
  • Antirheumatic Agents
  • Cytochrome P-450 CYP2C9 Substrates
ATC-CodeM04AB05
CAS number878672-00-5

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Solute carrier family 22 member 12MAFSELLDLVGGLGRFQVLQTMALMVSIMWLCTQSMLENFSAAVPSHRCW...unknowninhibitor
Solute carrier family 22 member 11MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCW...unknowninhibitor
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknownsubstrate
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknowninducer
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL2105720
PubChem 53465279
ChEMBL CHEMBL2105720
ChEBI CHEBI:90929
CCDC/CSD TIPQER, TIPQER01, TIPQER03, TIPQER04, WOHWIC, WOHWOI, WOHXAV, WOHXEZ, WOHXEZ01
COD 2021718, 2021719, 2021720, 2021722, 2021724, 2021723